NCT00543010终止3 期
MK0767 Glipizide Comparator Cardiac Safety Study (0767-018)
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 247
研究概览
简要总结
A study to evaluate the cardiac and metabolic effects of MK0767 in patients with Type 2 Diabetes.
This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 21 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •You are taking at least one medication for high blood sugar
- •Age 21 to 80
排除标准
- •History of Type 1 Diabetes Mellitus
- •Currently on estrogen replacement therapy regimen
- •Currently on a weight loss program with ongoing weight loss or taking medications for weight loss
- •Having surgery 30 days before starting the study
- •Have taken any other investigational drug in the past 90 days
- •Have Hepatitis B or C
- •Active liver or gallbladder disease
研究者
相似试验
终止
2 期
MK0767 in Type 2 Diabetes (0767-012)Type 2 Diabetes MellitusNCT00543556Merck Sharp & Dohme LLC514
终止
3 期
Dyslipidemia in Type 2 Diabetes (0767-034)Diabetes Mellitus, Type IIDyslipidemiaNCT00547274Merck Sharp & Dohme LLC111
终止
3 期
MK0767 and Sulfonylurea Combination Study (0767-027)Diabetes Mellitus, Type 2NCT00543491Merck Sharp & Dohme LLC129
终止
2 期
Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypertension (0736-007)Type 2 Diabetes MellitusHypertensionNCT00806585Merck Sharp & Dohme LLC620
已完成
1 期
Clinical Assessment of GSK716155 for Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT00530309GlaxoSmithKline40